Sort
48,018 grants matching “immunotherapy”
Mouse models of Kras-mutant colorectal cancer
$614,235Kevin Michael Haigis · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
$614,234Robert J Gray · Dana-Farber Cancer Inst · U01 · FY2022 · CA
A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria
$614,218Molly A Hughes · University Of Virginia · R01 · FY2024 · AI
TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPY
$614,214Todd A Fehniger · Washington University · R01 · FY2018 · CA
TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPY
$614,214Todd A Fehniger · Washington University · R01 · FY2017 · CA
TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPY
$614,214Todd A Fehniger · Washington University · R01 · FY2020 · CA
MECHANISMS OF RESISTANCE TO IMMUNOTHERAPY IN OSTEOSARCOMA
$614,209Regents Of The University Of Minnesota · · FY2018 · Department of the Army
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors
$614,124Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2025 · CA
Metabolic impact on T cell-mediated cancer immunity and therapy
$614,115Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Targeting LIF/LIFR in pancreatic cancer
$614,006Hareesh Babu Nair · Evestra, Inc. · R44 · FY2020 · CA
Attenuating Inflammation to Restore GI Tract Integrity and Reduce Viral Reservoirs During cART
$614,002Jacob D Estes · Oregon Health & Science University · R01 · FY2020 · DK
Immune Mechanisms in Ocular Graft versus Host Disease
$613,998Victor L Perez · University Of Miami School Of Medicine · R01 · FY2014 · EY
Regulation of ACAID by lymphocytes with NK markers
$613,958Joan Stein-Streilein · Schepens Eye Research Institute · R01 · FY2010 · EY
Programmable encapsulation systems to improve delivery of therapeutic bacteria
$613,945Tal Danino · Columbia Univ New York Morningside · R01 · FY2023 · EB
Novel immunological biomarkers ovarian cancer prognosis
$613,871Brahm H. Segal · Roswell Park Cancer Institute Corp · R01 · FY2019 · CA
Adoptive T Cell Therapy for Pancreatic Cancer
$613,867Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome
$613,864Verena Staedtke · Johns Hopkins University · U01 · FY2023 · CA
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
$613,843Donald Ym Leung · National Jewish Health · U01 · FY2023 · AR
Immune Impact on Cancer Chemoresistance
$613,838Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Immune Impact on Cancer Chemoresistance
$613,838Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2021 · CA
Developing an Oncology Workforce for the 21st Century
$613,810Olufunmilayo I Olopade · University Of Chicago · K12 · FY2020 · CA
ITIM-receptors for cancer treatment
$613,805Chengcheng Zhang · Ut Southwestern Medical Center · R01 · FY2020 · CA
IMMUNOSUPPRESSIVE FACTORS CONTRIBUTING TO IMMUNOTHERAPY RESISTANCE IN ENDOMETRIAL CANCER WITH DEFICIENT MISMATCH REPAIR SYSTEM
$613,793Magee-Womens Research Institute And Foundation · · FY2025 · Defense Health Agency
Naive T cells in Cancer Immune Evasion and Immunotherapy
$613,750Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2017 · CA
Gene Transfer and Somatic Cell Enginerring
$613,728Xiuyan Wang · Sloan-Kettering Inst Can Research · P30 · FY2025 · CA